BIOL Key Stats
- BIOLASE Added to Two Major Indices for 2013 Marketwired Jun 17
- Preliminary Russell 3000 Addition Pushing Stocks Around Street Insider Jun 17
- WallachBeth Capital Starts Biolase (BIOL) at Buy Street Insider Jun 17
- Coverage initiated on Biolase by WallachBeth Jun 16
- BIOLASE Adds Two New Independent Directors to Its Board Marketwired Jun 10
- BIOLASE, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Cha... Jun 10
- BIOLASE Names Current Director Alexander K. Arrow President and Chief Operating ... Jun 7
- BIOLASE Holds Annual Meeting of Shareholders Marketwired Jun 7
- BIOLASE, INC Files SEC form 8-K, Submission of Matters to a Vote of Security Hol... Jun 6
- BIOLASE, Inc. Responds to Shareholder Inquiries Marketwired Jun 6
BIOL Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Biolase is up 82.98% over the last year vs S&P 500 Total Return up 24.49%, AngioDynamics down 9.34%, and ResMed up 50.87%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for BIOL
Pro Strategies Featuring BIOL
Did Biolase make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.